经皮耳迷走神经刺激联合隐神经阻滞在膝骨关节炎中的疗效观察——一项随机对照试验

注册号:

Registration number:

ChiCTR2600118698 

最近更新日期:

Date of Last Refreshed on:

2026-02-10 09:51:27 

注册时间:

Date of Registration:

2026-02-10 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

经皮耳迷走神经刺激联合隐神经阻滞在膝骨关节炎中的疗效观察——一项随机对照试验

Public title:

Observation of the Efficacy of Percutaneous Auricular Vagus Nerve Stimulation Combined with Sphenopalatine Ganglion Block in Knee Osteoarthritis: A Randomized Controlled Trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

经皮耳迷走神经刺激联合隐神经阻滞在膝骨关节炎中的疗效观察——一项随机对照试验

Scientific title:

Observation of the Efficacy of Percutaneous Auricular Vagus Nerve Stimulation Combined with Sphenopalatine Ganglion Block in Knee Osteoarthritis: A Randomized Controlled Trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

汪强 

研究负责人:

王炎 

Applicant:

Wang Qiang 

Study leader:

Wang Yan 

申请注册联系人电话:

Applicant telephone:

+86 189 5630 7123

研究负责人电话:

Study leader's
telephone:

+86 138 5658 6040

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2445012333@stu.ahmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

ch2004640029@fy.ahmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

安徽省合肥市巢湖市巢湖北路64号

研究负责人通讯地址:

安徽省合肥市巢湖市巢湖北路64号

Applicant address:

No. 64, Chaohu North Road, Juchao District, Chaohu City, Anhui Province

Study leader's address:

No. 64, Chaohu North Road, Juchao District, Chaohu City, Anhui Province

申请注册联系人邮政编码:

Applicant postcode:

238000

研究负责人邮政编码:

Study leader's postcode:

238000

申请人所在单位:

安徽医科大学第四附属医院

Applicant's institution:

The Four Affiliated Hospital of Anhui Medical University

研究负责人所在单位:

安徽医科大学第四附属医院

Affiliation of the Leader:

The Four Affiliated Hospital of Anhui Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KYXM-202512-023

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

安徽医科大学附属巢湖医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Chaohu Hospital Affiliated to Anhui Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2026-01-09 00:00:00

伦理委员会联系人:

许笑笑

Contact Name of the ethic committee:

Xu Xiaoxiao

伦理委员会联系地址:

安徽省合肥市巢湖市巢湖北路64号

Contact Address of the ethic committee:

No. 64, Chaohu North Road, Juchao District, Chaohu City, Anhui Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 551 8232 4252

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

安徽医科大学第四附属医院

Primary sponsor:

The Four Affiliated Hospital of Anhui Medical University

研究实施负责(组长)单位地址:

安徽省合肥市巢湖市巢湖北路64号

Primary sponsor's address:

No. 64, Chaohu North Road, Juchao District, Chaohu City, Anhui Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽省

市(区县):

合肥

Country:

China

Province:

Anhui

City:

Hefei

单位(医院):

安徽医科大学第四附属医院

具体地址:

安徽省合肥市巢湖市巢湖北路64号

Institution
hospital:

The Four Affiliated Hospital of Anhui Medical University

Address:

No. 64, Chaohu North Road, Juchao District, Chaohu City, Anhui Province

经费或物资来源:

自筹经费

Source(s) of funding:

Self-financing

研究疾病:

膝骨关节炎  

Target disease:

Knee osteoarthritis

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1. 主要目的:探讨经皮耳迷走神经刺激联合隐神经阻滞可以增强神经阻滞作用时间,加速患者康复。 2. 次要目的:探讨经皮耳迷走神经联合隐神经阻滞可以减轻患者痛苦,加速康复,提高生活质量。为临床治疗膝骨关节炎提供一种新的治疗思路。  

Objectives of Study:

1. Primary Objective: To explore whether percutaneous auricular vagus nerve stimulation combined with obturator nerve block can prolong the duration of nerve block and accelerate patient recovery. 2. Secondary Objective: To investigate whether percutaneous auricular vagus nerve stimulation combined with obturator nerve block can relieve patient pain, speed up recovery, and improve quality of life, providing a new treatment approach for clinical management of knee osteoarthritis.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.有精神病史、神经系统疾病、心理疾病者,对局麻药物过敏的患者,无法正常沟通和交流者,使用抗抑郁、抗焦虑药物患者; 2.不符合膝骨关节炎诊断的患者。

Exclusion criteria:

1.Patients with a history of mental illness, neurological disorders, psychological disorders, allergy to local anesthetics, inability to communicate normally, or those taking antidepressants or anti-anxiety medications; 2.Patients who do not meet the diagnostic criteria for knee osteoarthritis.

研究实施时间:

Study execute time:

From 2026-02-10 00:00:00 To 2026-05-20 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-02-15 00:00:00 To 2026-05-15 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

50

Group:

Experimental group

Sample size:

干预措施:

于早餐后30min与晚餐后30min分别予以25HZ,250us,电流强度为0.25mA-2.0mA的迷走神经刺激。每次持续30min,持续7天。电流强度从0.25nA开始慢慢增加0.1mA,直至患者感觉刺痛但没有疼痛不适的情况,最高为2mA。每次刺激前先打开60s,后关闭10s,再打开60s以让患者适应

干预措施代码:

Intervention:

Vagus nerve stimulation was applied 30 minutes after breakfast and 30 minutes after dinner at 25 Hz, 250 μs, with a current intensity of 0.25 mA to 2.0 mA. Each session lasted 30 minutes and continued for 7 days. The current intensity started at 0.25 mA and was gradually increased by 0.1 mA until the patient felt a tingling sensation without pain or discomfort, with a maximum of 2 mA. Before each stimulation, the device was turned on for 60 seconds, then off for 10 seconds, and then on again for 60 seconds to allow the patient to adapt.

Intervention code:

组别:

对照组

样本量:

50

Group:

Control group

Sample size:

干预措施:

于早餐后30min与晚餐后30min进行25HZ,250us,电流强度为0.25mA-2.0mA的迷走神经刺激,每次持续30min,持续7天。每次刺激前先打开60s,后关闭,不再打开

干预措施代码:

Intervention:

Vagus nerve stimulation was performed 30 minutes after breakfast and 30 minutes after dinner at 25 Hz, 250 μs, with a current intensity of 0.25 mA–2.0 mA, each session lasting 30 minutes for 7 days. Each stimulation session was preceded by turning it on for 60 seconds, then turning it off and not turning it on again.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

安徽 

市(区县):

合肥 

Country:

China

Province:

Anhui

City:

Hefei

单位(医院):

安徽医科大学第四附属医院 

单位级别:

三甲 

Institution
hospital:

the Fourth Affiliated Hospital of Anhui Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

两组患者在治疗7天后VAS=0到VAS≥4的发生率

指标类型:

主要指标

Outcome:

Incidence of VAS=0 to VAS>=4 after 7 days of treatment in the two groups of patients

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

神经阻滞前(T0),治疗第三天(T1),治疗第5天(T2),出院后1周(T3),出院后4周(T4),阻滞后8周(T5)的VAS评分

指标类型:

次要指标

Outcome:

VAS scores before nerve block (T0), on the third day of treatment (T1), on the fifth day of treatment (T2), one week after discharge (T3), four weeks after discharge (T4), and eight weeks after block (T5)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

匹兹堡睡眠质量评分

指标类型:

次要指标

Outcome:

Pittsburgh Sleep Quality Index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗过程中服用曲马多的总量

指标类型:

次要指标

Outcome:

Total amount of tramadol taken during treatment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

焦虑量表评分(S-AI)

指标类型:

次要指标

Outcome:

Anxiety Scale Score (S-AI)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良反应:恶心,头晕等

指标类型:

次要指标

Outcome:

Adverse reactions: nausea, dizziness, etc.

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由独立第三方用计算机生成随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

An independent third party computer generated a random number table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

预计2027年5月公开原始数据,ResMan, http://www.medresman.org.cn.

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The raw data is expected to be released in May 2026 ResMan, http://www.medresman.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集由研究者设计病例记录表,对患者的基本信息进行登记,将术中观察指标及时记录并整理。术后将患者的信息及指标记录在电子数据表格中,方便保存及管理,也便于之后的数据统计分析。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection involved the development of a comprehensive case record table, where the researchers registered patients' basic information and promptly recorded and organized intraoperative observation indicators. Subsequently, post-operation patient information and indicators were documented in an electronic data form for convenient storage, management, and future statistical analysis.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-02-10 09:49:55